Daiwa Securities Group Inc. Acquires 3,908 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Daiwa Securities Group Inc. increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 12.6% during the 4th quarter, Holdings Channel reports. The fund owned 34,983 shares of the medical research company’s stock after buying an additional 3,908 shares during the quarter. Daiwa Securities Group Inc.’s holdings in IQVIA were worth $8,094,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Norges Bank acquired a new stake in IQVIA in the 4th quarter valued at approximately $408,232,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its position in IQVIA by 1,852.5% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,066,764 shares of the medical research company’s stock valued at $423,466,000 after buying an additional 1,960,914 shares during the last quarter. Alliancebernstein L.P. raised its position in IQVIA by 19.1% in the 2nd quarter. Alliancebernstein L.P. now owns 5,942,761 shares of the medical research company’s stock valued at $1,335,754,000 after buying an additional 952,850 shares during the last quarter. AMF Tjanstepension AB acquired a new stake in IQVIA in the 3rd quarter valued at approximately $148,096,000. Finally, Eagle Asset Management Inc. acquired a new stake in IQVIA in the 3rd quarter valued at approximately $102,982,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 0.0 %

IQV stock opened at $227.17 on Friday. The business’s 50 day simple moving average is $244.62 and its 200 day simple moving average is $221.41. The firm has a market capitalization of $41.23 billion, a PE ratio of 31.16, a PEG ratio of 2.20 and a beta of 1.50. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.82 by $0.02. The business had revenue of $3.87 billion during the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. During the same period in the previous year, the company posted $2.54 EPS. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 10.11 EPS for the current year.

Insider Activity at IQVIA

In related news, insider Kevin C. Knightly sold 8,607 shares of the business’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the sale, the insider now directly owns 5,251 shares in the company, valued at approximately $1,313,642.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Kevin C. Knightly sold 8,607 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the sale, the insider now directly owns 5,251 shares in the company, valued at approximately $1,313,642.67. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the sale, the insider now owns 20,836 shares of the company’s stock, valued at $5,031,894. The disclosure for this sale can be found here. Insiders sold 41,285 shares of company stock worth $10,331,003 in the last ninety days. 1.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on IQV shares. Barclays lifted their target price on IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. BTIG Research assumed coverage on IQVIA in a research report on Tuesday, February 13th. They set a “buy” rating and a $285.00 price target on the stock. Guggenheim lowered IQVIA from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Evercore ISI boosted their price target on IQVIA from $255.00 to $265.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 15th. Finally, UBS Group boosted their price target on IQVIA from $240.00 to $300.00 and gave the stock a “buy” rating in a research report on Thursday, February 15th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $256.80.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.